| Periodo | Margine operativo | Var. |
| 2019 | -11288.89% | +4340.42% |
| 2018 | -254.23% | -99.72% |
| 2017 | -91775.61% | +41.91% |
| 2016 | -64673.47% | — |
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune and autoimmune-related diseases. Its primary product candidate is FB102, a proprietary anti-CD122 monoclonal antibody designed to address unmet needs in conditions such as celiac disease, vitiligo, alopecia areata, and potentially type 1 diabetes. The company advances FB102 through clinical programs, including a phase 2 trial in celiac disease and phase 1b trials in vitiligo and alopecia areata, with research and development centered on clinical trials, manufacturing, and related preclinical activities. Forte Biosciences, Inc. concentrates its efforts on this single lead program to explore its potential across multiple indications sharing similar immune pathways. Headquartered in Dallas, Texas, the company operates within the biopharmaceutical sector, dedicating resources to generating clinical data and funding development through its core activities.